

What We Need to Know before Starting Clinical Amyloid PET Imaging

■ Foreword	Kazunari Ishii et al	1175
■ Amyloid PET using C-11 PiB	Takashi Kato	1177
■ Amyloid PET with F-18 labeled florbetapir, flutemetamol, and florbetaben focusing on the appropriate use guidelines	Kenji Ishii	1185
■ Could next generation amyloid ligands become de facto standards?	Hitoshi Shimada	1193
■ Plasma biomarker for cerebral amyloid deposition using mass spectrometry	Naoki Kaneko	1199
* * *		
■ N1 metastases diagnosed by ¹⁸ F-FDG-PET/CT in esophageal squamous cell cancer and its clinically use for radiation treatment field	Ichiro Ogino et al	1207
■ Initial experience of ¹⁷⁷ Lu PSMA radioligand therapy in Australia for Japanese metastatic castration resistant prostate cancer patients	Kenta Miki et al	1213
■ Monitoring tumor response to chemotherapy using diffusionweighted whole-body imaging with background body signal suppression in malignant lymphoma	Yumiko Kono et al	1221
■ A case of fungal pulmonary thromboembolism with FDG uptake on PET/CT	Ryota Nagao et al	1231
■ A case of huge pseudotumor caused by adverse reactions to metal debris in hip replacement	Kazuki Urata et al	1237

Editors

Yutaka Imai (Tokai University School of Medicine)
Takehiko Gokan (Showa University School of Medicine)
Yasuyuki Kurihara (St. Luke's International Hospital)
Jun Hashimoto (Tokai University School of Medicine)
Harushi Mori (Jichi Medical University)
Katsumasa Nakamura (Hamamatsu University School of Medicine)

● Published Monthly by KANEHARA SHUPPAN Co. LTD. ● P.O.Box No.1 Hongo Post Office Tokyo 113-0034, Japan
● Annual Subscription Price: ¥39,700(excluding tax)(Postal charge not included)